US Diabetes Care Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 32.59 Billion |
| Market Size (2029) | USD 39.08 Billion |
| CAGR (2024 - 2029) | 3.70 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
US Diabetes Care Drugs Market Analysis
The US Diabetes Care Drugs Market size is estimated at USD 32.59 billion in 2024, and is expected to reach USD 39.08 billion by 2029, growing at a CAGR of 3.70% during the forecast period (2024-2029).
The prevalence of diabetes in the United States is rapidly increasing, as indicated by the latest data from the CDC's National Diabetes Statistics Report for 2022. The report estimates that there are now approximately 37.3 million cases of diabetes in the country. This accounts for 11.3% of the U.S. population.
Out of these cases, around 28.7 million individuals have already been diagnosed with diabetes, while approximately 8.6 million people remain undiagnosed. It is important to note that diabetes affects individuals from all social, economic, and ethnic backgrounds. Furthermore, nearly half of the population aged 65 years or older, which amounts to 26.4 million people, have prediabetes.
According to the World Health Organization (WHO), the risk of diabetes has increased in North America due to the aging population. With advancements in healthcare, people are living longer, resulting in a significant percentage of the aging population being diagnosed with diabetes. The rising number of diabetes cases includes individuals who have recently developed the condition, particularly young individuals with unhealthy lifestyles. Additionally, there is an increase in the number of older adults who have been diagnosed with diabetes due to the availability of newer tests and increased screening.
Based on drugs, the insulin segment holds a significant share in the market. Over 100 million people around the world need insulin, including all the people suffering from Type-1 diabetes and between 10% and 25% of people with Type-2 diabetes. Production of insulin is very complex, and there are very few companies in the market that manufacture insulin. Due to this, there is high competition between these manufacturers, who always strive to meet the patient's needs to supply the best-quality insulin.
US Diabetes Care Drugs Market Trends
Oral-Anti Diabetes Drugs Segment is Having the Highest Market Share in Current Year
The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 5.4 % during the forecast period, mainly due to the demand from the diabetes population, which was more than 26 million by the end of the forecast period.
According to the International Diabetes Federation, Type 1 diabetes patients spend most of their money on insulin medicines. Only a small percentage of Type 2 diabetes patients require insulin. Although Type 1 diabetes affects just 10% of the population, their insulin consumption is greater. Increased knowledge of the advantages of insulin for diabetes patients, particularly in emerging nations, is driving the demand for insulin. Other reasons, such as quick advancement in insulin delivery methods, medication and analog research by major pharmaceutical firms, and an increase in the elderly and obese population, may fuel the insulin market's growth.
In the Oral Anti Diabetes Drugs segment, Metformin has the highest share. Metformin is a biguanide medication used to treat type 2 diabetes. It is given for "off-label" usage in patients suffering from diseases such as insulin resistance. Since introducing Metformin into T2DM therapy, many patients have been effectively treated with this internationally available medicine with a favorable risk/benefit profile recommended as a first-line prescription by IDF guidelines.
As a result, Metformin remains the most prescribed oral antidiabetic drug globally, accounting for 45-50% of all prescriptions and being used by over 150 million individuals each year. Long-term favorable experience with metformin usage, solid evidence of clinical efficacy and safety, high adherence rate, cheap cost, broad availability, and cost-effectiveness all contribute to the large market share.
Thus, the above factors are expected to drive the market growth over the forecast period.
Increasing Diabetes Population in the United States
The United States dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs. The United States is expected to grow tremendously during the forecast period, owing to factors such as the high prevalence of obesity and increasing awareness regarding diabetes care. North America remained the largest market for insulin drugs, primarily due to high demand from the United States. Diabetic drugs are medicines developed to stabilize and control blood glucose levels among people with diabetes.
In July 2022, Zydus Lifesciences announced that it had received final approval from the USFDA to market Empagliflozin and Metformin Hydrochloride tablets in multiple strengths. Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. They are also used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.
Thus, the above factors are expected to drive the market growth over the forecast period.
US Diabetes Care Drugs Industry Overview
Manufacturers have constantly innovated to compete and battle in the industry under study. According to a new study on the SGLT2 Class (Jardiance, Farxiga), medicine aids in treating renal and cardiovascular illnesses.
US Diabetes Care Drugs Market Leaders
-
Eli Lilly
-
Boehringer Ingelheim
-
Astrazeneca
-
Sanofi
-
NovoNordisk
*Disclaimer: Major Players sorted in no particular order
US Diabetes Care Drugs Market News
- June 2023: The initial allogeneic pancreatic islet cellular therapy, Lantidra, has been sanctioned by the U.S. Food and Drug Administration. This treatment, derived from deceased donor pancreatic cells, is specifically designed for individuals with type 1 diabetes. Lantidra is intended for adults who struggle to achieve target glycated hemoglobin levels due to frequent severe hypoglycemia episodes, despite undergoing intensive diabetes management and education.
- June 2023: The U.S. Food and Drug Administration has authorized the use of Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) in combination with diet and exercise to enhance blood sugar control in children aged 10 and older with type 2 diabetes. This approval marks the introduction of a new class of oral medications for managing pediatric type 2 diabetes.
US Diabetes Care Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Oral Anti-diabetic drugs
- 5.1.1 Biguanides
- 5.1.1.1 Metformin
- 5.1.2 Alpha-Glucosidase Inhibitors
- 5.1.2.1 Alpha-Glucosidase Inhibitors
- 5.1.3 Dopamine D2 receptor agonist
- 5.1.3.1 Bromocriptin
- 5.1.4 SGLT-2 inhibitors
- 5.1.4.1 Invokana (Canagliflozin)
- 5.1.4.2 Jardiance (Empagliflozin)
- 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
- 5.1.4.4 Suglat (Ipragliflozin)
- 5.1.5 DPP-4 inhibitors
- 5.1.5.1 Onglyza (Saxagliptin)
- 5.1.5.2 Tradjenta (Linagliptin)
- 5.1.5.3 Vipidia/Nesina(Alogliptin)
- 5.1.5.4 Galvus (Vildagliptin)
- 5.1.6 Sulfonylureas
- 5.1.6.1 Sulfonylureas
- 5.1.7 Meglitinides
- 5.1.7.1 Meglitinides
-
5.2 Insulins
- 5.2.1 Basal or Long Acting Insulins
- 5.2.1.1 Lantus (Insulin Glargine)
- 5.2.1.2 Levemir (Insulin Detemir)
- 5.2.1.3 Toujeo (Insulin Glargine)
- 5.2.1.4 Tresiba (Insulin Degludec)
- 5.2.1.5 Basaglar (Insulin Glargine)
- 5.2.2 Bolus or Fast Acting Insulins
- 5.2.2.1 NovoRapid/Novolog (Insulin Aspart)
- 5.2.2.2 Humalog (Insulin Lispro)
- 5.2.2.3 Apidra (Insulin Glulisine)
- 5.2.3 Traditional Human Insulins
- 5.2.3.1 Novolin/Actrapid/Insulatard
- 5.2.3.2 Humulin
- 5.2.3.3 Insuman
- 5.2.4 Biosimilar Insulins
- 5.2.4.1 Insulin Glargine Biosimilars
- 5.2.4.2 Human Insulin Biosimilars
-
5.3 Combination drugs
- 5.3.1 Insulin combinations
- 5.3.1.1 NovoMix (Biphasic Insulin Aspart)
- 5.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
- 5.3.1.3 Xultophy (Insulin Degludec and Liraglutide)
- 5.3.2 Oral Combinations
- 5.3.2.1 Janumet (Sitagliptin and Metformin)
-
5.4 Non-Insulin Injectable drugs
- 5.4.1 GLP-1 receptor agonists
- 5.4.1.1 Victoza (Liraglutide)
- 5.4.1.2 Byetta (Exenatide)
- 5.4.1.3 Bydureon (Exenatide)
- 5.4.1.4 Trulicity (Dulaglutide)
- 5.4.1.5 Lyxumia (Lixisenatide)
- 5.4.2 Amylin Analogue
- 5.4.2.1 Symlin (Pramlintide)
6. MARKET INDICATORS
- 6.1 Type-1 Diabetic Population
- 6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Takeda
- 7.1.2 Novo Nordisk
- 7.1.3 Pfizer
- 7.1.4 Eli Lilly
- 7.1.5 Janssen Pharmaceuticals
- 7.1.6 Astellas
- 7.1.7 Boehringer Ingelheim
- 7.1.8 Merck And Co.
- 7.1.9 AstraZeneca
- 7.1.10 Bristol Myers Squibb
- 7.1.11 Novartis
- 7.1.12 Sanofi
- *List Not Exhaustive
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityUS Diabetes Care Drugs Industry Segmentation
Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin or the body's cells do not respond properly to insulin, or both. The United States diabetes care drugs market is segmented into drugs. The report offers the value (in USD) and volume (in Units) for the above segments.
| Oral Anti-diabetic drugs | Biguanides | Metformin |
| Oral Anti-diabetic drugs | Alpha-Glucosidase Inhibitors | Alpha-Glucosidase Inhibitors |
| Oral Anti-diabetic drugs | Dopamine D2 receptor agonist | Bromocriptin |
| Oral Anti-diabetic drugs | SGLT-2 inhibitors | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Suglat (Ipragliflozin) | ||
| Oral Anti-diabetic drugs | DPP-4 inhibitors | Onglyza (Saxagliptin) |
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina(Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Oral Anti-diabetic drugs | Sulfonylureas | Sulfonylureas |
| Oral Anti-diabetic drugs | Meglitinides | Meglitinides |
| Insulins | Basal or Long Acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | ||
| Toujeo (Insulin Glargine) | ||
| Tresiba (Insulin Degludec) | ||
| Basaglar (Insulin Glargine) | ||
| Insulins | Bolus or Fast Acting Insulins | NovoRapid/Novolog (Insulin Aspart) |
| Humalog (Insulin Lispro) | ||
| Apidra (Insulin Glulisine) | ||
| Insulins | Traditional Human Insulins | Novolin/Actrapid/Insulatard |
| Humulin | ||
| Insuman | ||
| Insulins | Biosimilar Insulins | Insulin Glargine Biosimilars |
| Human Insulin Biosimilars | ||
| Combination drugs | Insulin combinations | NovoMix (Biphasic Insulin Aspart) |
| Ryzodeg (Insulin Degludec and Insulin Aspart) | ||
| Xultophy (Insulin Degludec and Liraglutide) | ||
| Combination drugs | Oral Combinations | Janumet (Sitagliptin and Metformin) |
| Non-Insulin Injectable drugs | GLP-1 receptor agonists | Victoza (Liraglutide) |
| Byetta (Exenatide) | ||
| Bydureon (Exenatide) | ||
| Trulicity (Dulaglutide) | ||
| Lyxumia (Lixisenatide) | ||
| Non-Insulin Injectable drugs | Amylin Analogue | Symlin (Pramlintide) |
US Diabetes Care Drugs Market Research FAQs
How big is the US Diabetes Care Drugs Market?
The US Diabetes Care Drugs Market size is expected to reach USD 32.59 billion in 2024 and grow at a CAGR of 3.70% to reach USD 39.08 billion by 2029.
What is the current US Diabetes Care Drugs Market size?
In 2024, the US Diabetes Care Drugs Market size is expected to reach USD 32.59 billion.
Who are the key players in US Diabetes Care Drugs Market?
Eli Lilly, Boehringer Ingelheim, Astrazeneca, Sanofi and NovoNordisk are the major companies operating in the US Diabetes Care Drugs Market.
What years does this US Diabetes Care Drugs Market cover, and what was the market size in 2023?
In 2023, the US Diabetes Care Drugs Market size was estimated at USD 31.38 billion. The report covers the US Diabetes Care Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the US Diabetes Care Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
United States Diabetes Care Drugs Industry Report
Statistics for the 2024 United States Diabetes Care Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. United States Diabetes Care Drugs analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
